For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation ...
Apr 13, 2022
0
9
A systematic review and meta-analysis of randomized control trials (RCTs) found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce hospitalizations and may reduce cardiovascular deaths among people experiencing ...
Apr 11, 2022
0
1
A recent study published in the journal Molecular Therapy - Nucleic Acids on the harmful effects of acute myocardial infarction opens the door to the administration of a molecule (urocortin-2) as a potential treatment to ...
Apr 5, 2022
0
4
Patients who received an implantable heart rhythm monitor after suffering a heart attack did not have fewer subsequent cardiovascular events overall, but a subset of patients whose heart attack was classified as non-ST segment ...
Apr 5, 2022
0
32
People who survive an ischemic stroke are much more likely to develop major heart complications during the first month after their stroke, and, as a result, they also have an increased risk of death, heart attack or another ...
Mar 31, 2022
0
9
A study led by the UGR reveals that men with periodontitis who are also diagnosed with erectile dysfunction are almost four times more likely to suffer a major adverse cardiovascular event (MACE).
Mar 23, 2022
0
12
The attack of the COVID-19 virus on the human heart is completely hidden from view, revealed only by the damage that's left behind.
Mar 9, 2022
0
5
The research groups of Jeroen Bakkers (Hubrecht Institute/UMC Utrecht) and Toon van Veen (UMC Utrecht) report the first patient-specific model for the heart disease arrhythmogenic cardiomyopathy (ACM). They were able to simulate ...
Dec 9, 2021
0
68
European Society of Cardiology (ESC) guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic is published today in the European Heart Journal.
Nov 16, 2021
0
4
Adults treated with empagliflozin during hospitalization for acute heart failure experienced a clinical benefit such as increased survival, lower risk of heart failure hospital readmission and an overall improvement in their ...
Nov 15, 2021
0
3
